Category Archives: Biotech

Monsanto's Rat Tumor Scare: A Wake-Up Call for the Pharma Industry?

By Guest Blogger | Published: September 25, 2012

ARE Monsanto’s RAT-TUMOUR SCARES A WAKE-UP CALL TO THE PHARMA INDUSTRY? By Reflector, Brussels correspondent. The furore that burst across Brussels in late September over reported findings of tumors in rats fed with genetically modified maize may seem only tangentially related to the concerns of European pharmaceutical executives — but the significance of the debate it has [...]

Also posted in Europe, Gene therapy, Guest Blog, Op-Ed, Safety, Technology | Tagged Biotechnology, EuropaBio, Europe, genetically modified organisms, GMOs, Mondanto, Safety | 2 Comments

New Non-Profit Alliance of Big Pharma Firms

By Guest Blogger | Published: September 21, 2012

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.

Also posted in Deals, Guest Blog | Tagged Abbott, AstraZeneca, Big Pharma, biopharm, BMS, Eli Lilly, Genentech, GlaxoSmithKline, Pfizer, Roche, Sanofi | Leave a comment

Taxpayers and Embryonic Stem Cell Research

By Ben Comer | Published: August 29, 2012

Last Friday, an appellate court upheld an earlier judgment allowing government to fund embryonic stem cell research for the development of new therapies. Biotechs and advocacy groups cheered the decision but uncertainty remains, in large part due to the possibility of a Romney administration in the White House.

Also posted in Legal, R&D, Regulatory, Strategy, Technology | Tagged Embryonic stem cell, HHS, Kathleen Sebelius, NIH, Regulatory Guidelines, Regulatory Science, Stem cell, Stem Cell Research | Leave a comment

Bristol-Myers Squibb's Summertime Blues

By Ben Comer | Published: August 7, 2012

The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar [...]

Also posted in Advertising, Deals, FDA, Legal, Marketing, R&D, Regulatory, Safety, Sales, Strategy, compliance, pricing | Tagged Bristol-Meyers Squibb, FDA, Office of Prescription Drug Promotion, OPDP, Regulatory, Untitled Letter | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

By Ben Comer | Published: August 1, 2012

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.

Also posted in Events, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Tagged AIDS, Antiretroviral drug, Bill & Melinda Gates Foundation, conference, Gilead Sciences, HIV, HIV/AIDS, NIAID | Leave a comment